RxDoctor Payments Data

Chassity Greer

Family · Byhalia, MSNPI 1558761668

Payments from drug & device makers

$522in general payments, 2019–2025

Across 13 payments — averaging $40.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$115
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$95
  • SK Life Science, Inc.$83
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$81
  • Sanofi Pasteur Inc.$47
  • Boehringer Ingelheim$35
  • plus $66 from 3 others

What the payments were for

  • Food & beverage$522100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$522 in reported general payments places this provider in the 55th percentile of 3,007 family providers in Mississippi.

See all family providers in Mississippi

Medicare billing

Part B allowed, 2024
$437
Medicare patients
27
Services billed
46

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide39$58,832
JardianceEmpagliflozin25$37,183
Synjardy XrEmpagliflozin/Metformin Hcl13$17,480
Lantus SolostarInsulin Glargine,hum.Rec.Anlog29$5,091
Novolog FlexpenInsulin Aspart13$2,581
Albuterol Sulfate HfaAlbuterol Sulfate50$2,218
Atorvastatin Calcium131$891
Amlodipine Besylate143$652
Losartan Potassium60$620
Levothyroxine Sodium27$528
Omeprazole35$509
Potassium Chloride17$414
Lovastatin22$392
Metformin Hcl57$377
Fluticasone Propionate22$344

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$27$58,83239 claims
Boehringer IngelheimJardiance, Synjardy Xr$35$54,66338 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 3,007 family providers in Mississippi.

Other family in Byhalia

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →